Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Abraham Scaria

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Human Gene Therapy|July 19, 2003
Myocardial expression of baculoviral p35 alleviates doxorubicin-induced cardiomyopathy in ratsTaro Date, Zhengyu Luo, Midori Yamakawa, et al.
Human Gene Therapy Methods|September 29, 2015
Analytical Ultracentrifugation as an Approach to Characterize Recombinant Adeno-Associated Viral VectorsBrenda Burnham, Shelley Nass, Elton Kong, et al.
Cardiovascular Research|July 19, 2002
Adenovirus-mediated expression of p35 prevents hypoxia/reoxygenation injury by reducing reactive oxygen species and caspase activityTaro Date, Adam J Belanger, Seibu Mochizuki, et al.
Investigative Ophthalmology & Visual Science|July 20, 2023
AAV Gene Augmentation of Truncated Complement Factor H Differentially Rescues Ocular Complement Dysregulation in a Mouse ModelDaniel Grigsby, Mikael Klingeborn, Una Kelly, et al.
Neurobiology of Aging|March 15, 2011
AAV5-mediated sFLT01 gene therapy arrests retinal lesions in Ccl2(-/-)/Cx3cr1(-/-) miceJingsheng Tuo, Ji-Jing Pang, Xiaoguang Cao, et al.
American Journal of Ophthalmology|December 6, 2024
Subretinal Gene Therapy Drug AGTC-501 for XLRP Phase 1/2 Multicenter Study (HORIZON): 24-Month Safety and Efficacy ResultsPaul Yang, David Birch, Andreas Lauer, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 28, 2010
Inhibition of choroidal neovascularization in a nonhuman primate model by intravitreal administration of an AAV2 vector expressing a novel anti-VEGF moleculeMichael Lukason, Elizabeth DuFresne, Hillard Rubin, et al.
Gene Therapy|May 23, 2018
Rationally designed AAV2 and AAVrh8R capsids provide improved transduction in the retina and brainJennifer A Sullivan, Lisa M Stanek, Michael J Lukason, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 2, 2010
Preclinical safety evaluation of AAV2-sFLT01- a gene therapy for age-related macular degenerationTimothy K Maclachlan, Michael Lukason, Margaret Collins, et al.
Molecular Therapy. Methods & Clinical Development|January 20, 2018
Universal Method for the Purification of Recombinant AAV Vectors of Differing SerotypesShelley A Nass, Maryellen A Mattingly, Denise A Woodcock, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Human Gene Therapy|July 19, 2003
Myocardial expression of baculoviral p35 alleviates doxorubicin-induced cardiomyopathy in ratsTaro Date, Zhengyu Luo, Midori Yamakawa, et al.
Human Gene Therapy Methods|September 29, 2015
Analytical Ultracentrifugation as an Approach to Characterize Recombinant Adeno-Associated Viral VectorsBrenda Burnham, Shelley Nass, Elton Kong, et al.
Cardiovascular Research|July 19, 2002
Adenovirus-mediated expression of p35 prevents hypoxia/reoxygenation injury by reducing reactive oxygen species and caspase activityTaro Date, Adam J Belanger, Seibu Mochizuki, et al.
Investigative Ophthalmology & Visual Science|July 20, 2023
AAV Gene Augmentation of Truncated Complement Factor H Differentially Rescues Ocular Complement Dysregulation in a Mouse ModelDaniel Grigsby, Mikael Klingeborn, Una Kelly, et al.
Neurobiology of Aging|March 15, 2011
AAV5-mediated sFLT01 gene therapy arrests retinal lesions in Ccl2(-/-)/Cx3cr1(-/-) miceJingsheng Tuo, Ji-Jing Pang, Xiaoguang Cao, et al.
American Journal of Ophthalmology|December 6, 2024
Subretinal Gene Therapy Drug AGTC-501 for XLRP Phase 1/2 Multicenter Study (HORIZON): 24-Month Safety and Efficacy ResultsPaul Yang, David Birch, Andreas Lauer, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 28, 2010
Inhibition of choroidal neovascularization in a nonhuman primate model by intravitreal administration of an AAV2 vector expressing a novel anti-VEGF moleculeMichael Lukason, Elizabeth DuFresne, Hillard Rubin, et al.
Gene Therapy|May 23, 2018
Rationally designed AAV2 and AAVrh8R capsids provide improved transduction in the retina and brainJennifer A Sullivan, Lisa M Stanek, Michael J Lukason, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 2, 2010
Preclinical safety evaluation of AAV2-sFLT01- a gene therapy for age-related macular degenerationTimothy K Maclachlan, Michael Lukason, Margaret Collins, et al.
Molecular Therapy. Methods & Clinical Development|January 20, 2018
Universal Method for the Purification of Recombinant AAV Vectors of Differing SerotypesShelley A Nass, Maryellen A Mattingly, Denise A Woodcock, et al.
Pageof 3